A Two-Stage, Phase 1/2, Open-Label Study of the Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome).

Trial Profile

A Two-Stage, Phase 1/2, Open-Label Study of the Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome).

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2017

At a glance

  • Drugs AGT 181 (Primary)
  • Indications Mucopolysaccharidosis I
  • Focus Adverse reactions; Proof of concept
  • Sponsors ArmaGen Technologies
  • Most Recent Events

    • 16 Feb 2017 Preliminary results (n=5) from the phase II portion of this trial presented at the 13th annual WORLDSymposium 2017, according to an ArmaGen Technologies media release.
    • 16 Feb 2017 Preliminary results (n=5) from the phase II portion of this trial published in an ArmaGen Technologies media release.
    • 07 Feb 2017 According to ArmaGen Technologies media release, initial data from this study will be presented at the 13th Annual WORLDSymposium 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top